WO2014099927A1 - Micro-organismes modifiés et procédés d'utilisation de ceux-ci pour produire de l'isoprène, du 2-méthyl-1-butanol, du 2-méthyl-1,3-butanediol, et/ou du 2-méthyl-but-2-én-1-ol - Google Patents

Micro-organismes modifiés et procédés d'utilisation de ceux-ci pour produire de l'isoprène, du 2-méthyl-1-butanol, du 2-méthyl-1,3-butanediol, et/ou du 2-méthyl-but-2-én-1-ol Download PDF

Info

Publication number
WO2014099927A1
WO2014099927A1 PCT/US2013/075692 US2013075692W WO2014099927A1 WO 2014099927 A1 WO2014099927 A1 WO 2014099927A1 US 2013075692 W US2013075692 W US 2013075692W WO 2014099927 A1 WO2014099927 A1 WO 2014099927A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
isoprene
butanol
butanediol
methylbut
Prior art date
Application number
PCT/US2013/075692
Other languages
English (en)
Inventor
Mateus Schreiner GARCEZ LOPES
Original Assignee
Braskem S/A Ap 09
Braskem America, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braskem S/A Ap 09, Braskem America, Inc. filed Critical Braskem S/A Ap 09
Publication of WO2014099927A1 publication Critical patent/WO2014099927A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/007—Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic

Definitions

  • Isoprene is also copolymerized for use as a synthetic elastomer in other products such as footwear, mechanical products, medical products, sporting goods, and latex.
  • isoprene can be obtained by fractionating petroleum, the purification on this material is expensive and time-consuming. Petroleum cracking of the C5 stream of hydrocarbons produce only 15% isoprene. Isoprene could be also produced by isobutylene carbonylation with methanol and by isopentene dehydrogenation. However, more economical methods for producing isoprene are needed. In particular, methods that produce isoprene at rates, titers, and purity that are sufficient to meet the demands of a robust commercial process are desirable. Also desired are systems for producing isoprene from inexpensive starting materials. SUMMARY
  • the present disclosure generally relates to microorganisms (e.g., non-naturally occurring microorganisms) that comprise one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of a carbon source (e.g., a fermentable carbon source) to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en- 1 -ol and the use of such microorganisms for the production of isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol.
  • a carbon source e.g., a fermentable carbon source
  • the present disclosure provides methods of co-producing isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol from a fermentable carbon source, the method comprising: providing a fermentable carbon source; contacting the fermentable carbon source with a microorganism comprising one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol and one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl- 1 ,3-butanediol,
  • the enzymes that catalyze the conversion of the fermentable carbon source to one or more intermediates in the pathway for the production of isoprene, 2-methyl-1 - butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol are set forth in any one of Tables 1 -2 or Figures 1 -2.
  • the enzymes that catalyze the conversion of the one or more intermediates to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol are set forth in any one of Tables 1-2 or Figures 1-2.
  • isoprene is produced, 2-methyl-1-butanol is produced, 2-methyl-1 ,3- butanediol is produced, 2-methylbut-2-en-1-ol is produced, isoprene and 2-methyl-1- butanol are produced, isoprene and , 2-methyl-1 ,3-butanediol are produced, isoprene and 2-methylbut-2-en-1-ol are produced, 2-methyl-1-butanol and 2-methyl-1 ,3-butanediol are produced, 2-methyl-1-butanol and 2-methylbut-2-en-1-ol are produced, 2-methyl-1 ,3- butanediol and 2-methylbut-2-en-1 -ol are produced; isoprene, 2-methyl-1-butanol, and 2- methyl-1 ,3-butanediol are produced; isoprene, 2-methyl-1-butanol, and 2- methyl-1 ,3-butanediol are produced
  • the microorganism is a bacteria selected from the genera consisting of: Burkholderia, Propionibacterium, Propionispira, Clostridium, Bacillus, Escherichia, Pelobacter, or Lactobacillus.
  • the microorganism is a eukaryote selected from the group consisting of yeast, filamentous fungi, protozoa, and algae.
  • the yeast is Saccharomyces cerevisiae, Zymomonas mobilis, or Pichia pastoris.
  • the fermentable carbon source comprises sugarcane juice, sugarcane molasses, hydrolyzed starch, hydrolyzed lignocellulosic materials, glucose, sucrose, fructose, lactate, lactose, xylose, pyruvate, or glycerol in any form or mixture thereof.
  • the fermentable carbon source is a monosaccharide, oligosaccharide, or polysaccharide.
  • the produced isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and 2- methylbut-2-en-1-ol are secreted by the microorganism into the fermentation media.
  • the method further comprises recovering the produced isoprene, 2-methyl- 1-butanol, 2-methyl-1 ,3-butanediol, and 2-methylbut-2-en-1-ol from the fermentation media.
  • the microorganism has been genetically modified to express the one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and 2-methylbut-2-en-1 -ol, and one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and 2- methylbut-2-en-1-ol.
  • the fermentable carbon source is contacted with the microorganism prior to expressing in the microorganism the one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1-butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol and the one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2- methylbut-2-en-1-ol.
  • the fermentable carbon source is contacted with the microorganism after expressing in the microorganism the one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1-butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol and the one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2- methylbut-2-en-1-ol.
  • the conversion of the fermentable carbon source to isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and 2-methylbut-2-en-1-ol is ATP positive and is combined with a NADH consuming pathway to provide an anaerobic process for isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol production.
  • the present disclosure also provides a microorganism comprising one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2- en-1 -ol and one or more polynucleotides that encode one or more enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol, wherein the one or more intermediates in the pathway for the co-production of isoprene, 2-methyl-1 -butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol
  • the enzymes that catalyze a conversion of the fermentable carbon source to one or more intermediates in the pathway for the production of isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol are set forth in any one of Tables 1 -2 or Figures 1 -2.
  • the enzymes that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol are set forth in any one of Tables 1-2 or Figures 1-2.
  • the microorganism is a bacteria selected from the genera consisting of: Burkholderia, Propionibacterium, Propionispira, Clostridium, Bacillus, Escherichia, Pelobacter, or Lactobacillus.
  • the microorganism is a eukaryote selected from the group consisting of yeast, filamentous fungi, protozoa, and algae.
  • the yeast is Saccharomyces cerevisiae, Zymomonas mobilis, or Pichia pastoris.
  • the microorganism has been genetically modified to express the one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol, and one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • Figure 1 depicts an exemplary pathway for the production of a 2- methylacetoacetyl-CoA intermediate, and exemplary pathways for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol via a 2-methylacetoacetyl-CoA intermediate.
  • Figure 2 depicts an exemplary pathway for the production of a 2- methylacetoacetyl-CoA intermediate, and exemplary pathways for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol via a 2-methylacetoacetyl-CoA intermediate as provided in Figure 1 .
  • Figure 3 depicts an exemplary pathway for the conversion of 2-methyl-1-butanol to 2-methyl-1-butene and the conversion of 2-methylbut-2-en-1 -ol, 2-methyl-1 ,3-butanediol, or 2-methyl-1-butanol to isoprene.
  • the present disclosure generally relates to microorganisms (e.g., non-naturally occurring microorganisms) that comprise one or more genetically modified pathways and uses of such microorganisms for the conversion of a fermentable carbon source to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol (see, Figures 1-2).
  • microorganisms may comprise one or more polynucleotides coding for enzymes that catalyze a conversion of a fermentable carbon source to isoprene, 2-methyl-
  • 2- methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol are further converted to isoprene including, for example, polyisoprene or another isoprene-containing polymer; and/or 2-methyl-1 -butanol is further converted to 2-methyl-isoprene (see, Figure 3).
  • This disclosure provides, in part, the discovery of novel enzymatic pathways including, for example, novel combinations of enzymatic pathways, for the production of isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol from a carbon source (e.g., a fermentable carbon source).
  • a carbon source e.g., a fermentable carbon source
  • isoprene is produced, 2-methyl-1-butanol is produced, 2-methyl-1 ,3-butanediol is produced, 2- methylbut-2-en-1-ol is produced, isoprene and 2-methyl-1 -butanol are produced, isoprene and , 2-methyl-1 ,3-butanediol are produced, isoprene and 2-methylbut-2-en-1-ol are produced, 2-methyl-1-butanol and 2-methyl-1 ,3-butanediol are produced, 2-methyl-1 - butanol and 2-methylbut-2-en-1-ol are produced, 2-methyl-1 ,3-butanediol and 2-methylbut- 2-en-1-ol are produced; isoprene, 2-methyl-1-butanol, and 2-methyl-1 ,3-butanediol are produced; isoprene, 2-methyl-1 -butanol, and 2-methyl-1 ,3-butanediol are
  • the methods provided herein provide end-results similar to those of sterilization without the high capital expenditure and continuing higher management costs that are typically required to establish and maintain sterility throughout a production process.
  • most industrial-scale isoprene production processes are operated in the presence of measurable numbers of bacterial contaminants due to the aerobic nature of their processes. It is believed that bacterial contamination of an isoprene production processes causes a reduction in product yield and an inhibition of growth of the microorganism producing isoprene.
  • the enzymatic pathways disclosed herein are advantageous over prior known enzymatic pathways for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3- butanediol, and/or 2-methylbut-2-en-1-ol in that the enzymatic pathways disclosed herein are anaerobic. While it is possible to use aerobic processes to produce isoprene, 2- methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol, anaerobic processes are preferred due to the risk incurred when olefins (which are by nature are explosive) are mixed with oxygen during the fermentation process, especially for isoprene fermentation.
  • olefins which are by nature are explosive
  • the supplementation of oxygen and nitrogen in a fermenter requires an additional investment for air compressor, fermenters (bubble column or air-lift fermenter), temperature control and nitrogen.
  • the presence of oxygen can also catalyze the polymerization of isoprene and can promote the growth of aerobic contaminants in the fermentor broth.
  • aerobic fermentation processes for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol present several drawbacks at industrial scale (where it is technically challenging to maintain aseptic conditions) such as the fact that: (i) greater biomass is obtained reducing overall yields on carbon for the desired products; (ii) the presence and oxygen favors the growth of contaminants (Weusthuis et al., 201 1 , Trends in Biotechnology, 201 1 , Vol. 29, No.
  • the steps involved in any and all of the methods described herein may be performed in any order and are not to be limited or restricted to the order in which they are particularly recited.
  • the present disclosure provides methods of producing isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol from a fermentable carbon source, comprising: providing a fermentable carbon source; contacting the fermentable carbon source with a microorganism comprising one or more polynucleotides coding for enzymes in a pathway that catalyzes a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol, and one or more polynucleotides coding for enzymes in a pathway that catalyze
  • expression of the one or more polynucleotides coding for the enzymes in the pathway that catalyzes a conversion of the fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol and one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the one or more intermediates to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol in the microorganism to produce isoprene, 2-methyl-1 - butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol may be performed prior to or after contacting the fermentable carbon source with a microorganism comprising the
  • biological activity when referring to a protein, polypeptide or peptide, may mean that the protein, polypeptide or peptide exhibits a functionality or property that is useful as relating to some biological process, pathway or reaction.
  • Biological or functional activity can refer to, for example, an ability to interact or associate with (e.g., bind to) another polypeptide or molecule, or it can refer to an ability to catalyze or regulate the interaction of other proteins or molecules (e.g., enzymatic reactions).
  • the term “culturing” may refer to growing a population of cells, e.g., microbial cells, under suitable conditions for growth, in a liquid or on solid medium.
  • the term “derived from” may encompass the terms originated from, obtained from, obtainable from, isolated from, and created from, and generally indicates that one specified material finds its origin in another specified material or has features that can be described with reference to the another specified material.
  • exogenous polynucleotide refers to any deoxyribonucleic acid that originates outside of the microorganism.
  • an expression vector may refer to a DNA construct containing a polynucleotide or nucleic acid sequence encoding a polypeptide or protein, such as a DNA coding sequence (e.g. gene sequence) that is operably linked to one or more suitable control sequence(s) capable of affecting expression of the coding sequence in a host.
  • control sequences include a promoter to affect transcription, an optional operator sequence to control such transcription, a sequence encoding suitable mRNA ribosome binding sites, and sequences which control termination of transcription and translation.
  • the vector may be a plasmid, cosmid, phage particle, bacterial artificial chromosome, or simply a potential genomic insert.
  • the vector may replicate and function independently of the host genome (e.g., independent vector or plasmid), or may, in some instances, integrate into the genome itself (e.g., integrated vector).
  • the plasmid is the most commonly used form of expression vector. However, the disclosure is intended to include such other forms of expression vectors that serve equivalent functions and which are, or become, known in the art.
  • the term "expression” may refer to the process by which a polypeptide is produced based on a nucleic acid sequence encoding the polypeptides (e.g., a gene). The process includes both transcription and translation.
  • the term "gene” may refer to a DNA segment that is involved in producing a polypeptide or protein (e.g., fusion protein) and includes regions preceding and following the coding regions as well as intervening sequences (introns) between individual coding segments (exons).
  • heterologous with reference to a nucleic acid, polynucleotide, protein or peptide, may refer to a nucleic acid, polynucleotide, protein or peptide that does not naturally occur in a specified cell, e.g., a host cell. It is intended that the term encompass proteins that are encoded by naturally occurring genes, mutated genes, and/or synthetic genes.
  • homologous with reference to a nucleic acid, polynucleotide, protein or peptide, refers to a nucleic acid, polynucleotide, protein or peptide that occurs naturally in the cell.
  • a "host cell” may refer to a cell or cell line, including a cell such as a microorganism which a recombinant expression vector may be transfected for expression of a polypeptide or protein (e.g., fusion protein).
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in total genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • a host cell may include cells transfected or transformed in vivo with an expression vector.
  • the term "introduced,” in the context of inserting a nucleic acid sequence or a polynucleotide sequence into a cell, may include transfection, transformation, or transduction and refers to the incorporation of a nucleic acid sequence or polynucleotide sequence into a eukaryotic or prokaryotic cell wherein the nucleic acid sequence or polynucleotide sequence may be incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed.
  • the genome of the cell e.g., chromosome, plasmid, plastid, or mitochondrial DNA
  • non-naturally occurring when used in reference to a microbial organism or microorganism of the invention is intended to mean that the microbial organism has at least one genetic alteration not normally found in a naturally occurring strain of the referenced species, including wild-type strains of the referenced species.
  • Genetic alterations include, for example, modifications introducing expressible nucleic acids encoding metabolic polypeptides, other nucleic acid additions, nucleic acid deletions and/or other functional disruption of the microbial organism's genetic material. Such modifications include, for example, coding regions and functional fragments thereof, for heterologous, homologous or both heterologous and homologous polypeptides for the referenced species.
  • Additional modifications include, for example, non-coding regulatory regions in which the modifications alter expression of a gene or operon.
  • Non-naturally occurring microbial organisms of the disclosure can contain stable genetic alterations, which refers to microorganisms that can be cultured for greater than five generations without loss of the alteration.
  • stable genetic alterations include modifications that persist greater than 10 generations, particularly stable modifications will persist more than about 25 generations, and more particularly, stable genetic modifications will be greater than 50 generations, including indefinitely.
  • Those skilled in the art will understand that the genetic alterations, including metabolic modifications exemplified herein, are described with reference to a suitable host organism such as E. coli and their corresponding metabolic reactions or a suitable source organism for desired genetic material such as genes for a desired metabolic pathway.
  • E. coli metabolic alterations exemplified herein can readily be applied to other species by incorporating the same or analogous encoding nucleic acid from species other than the referenced species.
  • Such genetic alterations include, for example, genetic alterations of species homologs, in general, and in particular, orthologs, paralogs or nonorthologous gene displacements.
  • operably linked may refer to a juxtaposition or arrangement of specified elements that allows them to perform in concert to bring about an effect.
  • a promoter may be operably linked to a coding sequence if it controls the transcription of the coding sequence.
  • a promoter may refer to a regulatory sequence that is involved in binding RNA polymerase to initiate transcription of a gene.
  • a promoter may be an inducible promoter or a constitutive promoter.
  • An inducible promoter is a promoter that is active under environmental or developmental regulatory conditions.
  • a polynucleotide or “nucleic acid sequence” may refer to a polymeric form of nucleotides of any length and any three-dimensional structure and single- or multi-stranded (e.g., single-stranded, double-stranded, triple-helical, etc.), which contain deoxyribonucleotides, ribonucleotides, and/or analogs or modified forms of deoxyribonucleotides or ribonucleotides, including modified nucleotides or bases or their analogs.
  • Such polynucleotides or nucleic acid sequences may encode amino acids (e.g., polypeptides or proteins such as fusion proteins).
  • polynucleotides which encode a particular amino acid sequence. Any type of modified nucleotide or nucleotide analog may be used, so long as the polynucleotide retains the desired functionality under conditions of use, including modifications that increase nuclease resistance (e.g., deoxy, 2'-0-Me, phosphorothioates, etc.). Labels may also be incorporated for purposes of detection or capture, for example, radioactive or nonradioactive labels or anchors, e.g., biotin.
  • polynucleotide also includes peptide nucleic acids (PNA).
  • Polynucleotides may be naturally occurring or non- naturally occurring.
  • the terms polynucleotide, nucleic acid, and oligonucleotide are used herein interchangeably.
  • Polynucleotides may contain RNA, DNA, or both, and/or modified forms and/or analogs thereof.
  • a sequence of nucleotides may be interrupted by non- nucleotide components.
  • One or more phosphodiester linkages may be replaced by alternative linking groups.
  • linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(0)S (thioate), P(S)S (dithioate), (0)NR 2 (amidate), P(0)R, P(0)OR', COCH 2 (formacetal), in which each R or R' is independently H or substituted or unsubstituted alkyl (1 -20 C) optionally containing an ether (-0-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. Polynucleotides may be linear or circular or comprise a combination of linear and circular portions.
  • a "protein” or “polypeptide” may refer to a composition comprised of amino acids and recognized as a protein by those of skill in the art.
  • the conventional one-letter or three-letter code for amino acid residues is used herein.
  • the terms protein and polypeptide are used interchangeably herein to refer to polymers of amino acids of any length, including those comprising linked (e.g., fused) peptides/polypeptides (e.g., fusion proteins).
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.
  • related proteins, polypeptides or peptides may encompass variant proteins, polypeptides or peptides.
  • Variant proteins, polypeptides or peptides differ from a parent protein, polypeptide or peptide and/or from one another by a small number of amino acid residues.
  • the number of different amino acid residues is any of about 1 , 2, 3, 4, 5, 10, 20, 25, 30, 35, 40, 45, or 50.
  • variants differ by about 1 to about 10 amino acids.
  • variants may have a specified degree of sequence identity with a reference protein or nucleic acid, e.g., as determined using a sequence alignment tool, such as BLAST, ALIGN, and CLUSTAL (see, infra).
  • variant proteins or nucleic acid may have at least about 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% amino acid sequence identity with a reference sequence.
  • the term “recovered,” “isolated,” “purified,” and “separated” may refer to a material (e.g., a protein, peptide, nucleic acid, polynucleotide or cell) that is removed from at least one component with which it is naturally associated.
  • these terms may refer to a material which is substantially or essentially free from components which normally accompany it as found in its native state, such as, for example, an intact biological system.
  • the term “recombinant” may refer to nucleic acid sequences or polynucleotides, polypeptides or proteins, and cells based thereon, that have been manipulated by man such that they are not the same as nucleic acids, polypeptides, and cells as found in nature.
  • Recombinant may also refer to genetic material (e.g., nucleic acid sequences or polynucleotides, the polypeptides or proteins they encode, and vectors and cells comprising such nucleic acid sequences or polynucleotides) that has been modified to alter its sequence or expression characteristics, such as by mutating the coding sequence to produce an altered polypeptide, fusing the coding sequence to that of another coding sequence or gene, placing a gene under the control of a different promoter, expressing a gene in a heterologous organism, expressing a gene at decreased or elevated levels, expressing a gene conditionally or constitutively in manners different from its natural expression profile, and the like.
  • genetic material e.g., nucleic acid sequences or polynucleotides, the polypeptides or proteins they encode, and vectors and cells comprising such nucleic acid sequences or polynucleotides
  • selective marker may refer to a gene capable of expression in a host cell that allows for ease of selection of those hosts containing an introduced nucleic acid sequence, polynucleotide or vector.
  • selectable markers include but are not limited to antimicrobial substances (e.g., hygromycin, bleomycin, or chloramphenicol) and/or genes that confer a metabolic advantage, such as a nutritional advantage, on the host cell.
  • nucleic acid, polynucleotides, proteins or polypeptides may mean that a nucleic acid, polynucleotide, protein or polypeptide comprises a sequence that has at least about 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% sequence identity, in comparison with a reference (e.g., wild-type) nucleic acid, polynucleotide, protein or polypeptide.
  • a reference e.g., wild-type
  • Sequence identity may be determined using known programs such as BLAST, ALIGN, and CLUSTAL using standard parameters.
  • BLAST Altshul et al. (1990) J. Mol. Biol. 215:403-410; Henikoff et al. (1989) Proc. Natl. Acad. Sci. 89:10915; Karin et al. (1993) Proc. Natl. Acad. Sci. 90:5873; and Higgins et al. (1988) Gene 73:237).
  • Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. Also, databases may be searched using FASTA (Person et al. (1988) Proc. Natl. Acad. Sci.
  • substantially identical polypeptides differ only by one or more conservative amino acid substitutions.
  • substantially identical polypeptides are immunologically cross-reactive.
  • substantially identical nucleic acid molecules hybridize to each other under stringent conditions (e.g., within a range of medium to high stringency).
  • transfection or “transformation” may refer to the insertion of an exogenous nucleic acid or polynucleotide into a host cell.
  • the exogenous nucleic acid or polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome.
  • transfecting or transfection is intended to encompass all conventional techniques for introducing nucleic acid or polynucleotide into host cells.
  • transfection techniques include, but are not limited to, calcium phosphate precipitation, DEAE-dextran- mediated transfection, lipofection, electroporation, and microinjection.
  • transformed may refer to a cell that has a non-native (e.g., heterologous) nucleic acid sequence or polynucleotide sequence integrated into its genome or as an episomal plasmid that is maintained through multiple generations.
  • non-native e.g., heterologous
  • vector may refer to a polynucleotide sequence designed to introduce nucleic acids into one or more cell types.
  • Vectors include cloning vectors, expression vectors, shuttle vectors, plasmids, phage particles, single and double stranded cassettes and the like.
  • wild-type As used herein, the term “wild-type,” “native,” or “naturally-occurring” proteins may refer to those proteins found in nature.
  • wild-type sequence refers to an amino acid or nucleic acid sequence that is found in nature or naturally occurring.
  • a wild-type sequence is the starting point of a protein engineering project, for example, production of variant proteins.
  • nucleic acids sequences are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
  • a microorganism may be modified (e.g., genetically engineered) by any method known in the art to comprise and/or express one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of a fermentable carbon source to one or more intermediates in a pathway for the production of isoprene, 2-methyl-1 -butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • Such enzymes may include any of those enzymes as are forth in any one of Figures 1-2.
  • the microorganism may be modified to comprise one or more polynucleotides coding for enzymes that catalyze a conversion of methylmalonyl-CoA, acryloyl-CoA, propionate and/or 2- ketobutyrate to propionyl-CoA, one or more enzymes that catalyze a conversion of pyruvate, acetaldehyde, and/or acetic acid to acetyl-CoA, one or more enzymes that catalyze a conversion of propionyl-CoA and acetyl-CoA to 2-methylacetoacetyl-CoA and one or more enzymes that catalyze a conversion of 2-methylacetoacetly-CoA to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • the microorganism further comprises one or more polynucleotides coding for enzymes that catalyze a conversion of a fermentable carbon source (e.g., glucose) to methylmalonyl-CoA, acryloyl-CoA, propionate, 2-ketobutyrate, pyruvate, acetaldehyde, and/or acetic acid.
  • a fermentable carbon source e.g., glucose
  • the one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of methylmalonyl-CoA, acryloyl-CoA, propionate, 2- ketobutyrate, pyruvate, acetaldehyde, acetic acid, and/or glucose to 2-methylacetoacetyl- CoA, and a conversion of 2-methylacetoacetyl-CoA to isoprene, 2-methyl-1 -butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol include:
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of acetyl-CoA and propionyl-CoA to 2-methylacetoacetyl-CoA (e.g., acetyl- CoA:propanoyl-CoA 2-C-acetyltransferase or 2-methylacetoacetyl-CoA thiolase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methylacetoacetyl-CoA to 2-methyl-3-hydroxybutyryl-CoA (e.g., 2-methyl- 3-hydroxybutyryl-CoA dehydrogenase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-3-hydroxybutyryl-CoA to 2-methyl-2-butenoyl-CoA (e.g., 3-Hydroxy-
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-2-butenoyl-CoA to 2-methyl-butanoyl-CoA e.g., 2-methyl-butanoyl- CoA dehydrogenase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-2-butanoyl-CoA to 2-methyl-1 -butanal e.g., 2-methyl-1 -butanal dehydrogenase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-2-butanoyl-CoA to 2-methyl-1 -butanol e.g., 2-methyl-2-butenoyl- CoA reductase (Afunctional)
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-2-butenoyl-CoA to 2-methyl-1 -but-2-enal e.g., 2-methyl-1 -but-2- enal dehydrogenase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-1 -but-2-enal to 2-methyl-1 -but-2-enol e.g., 2-methyl-1 -but-2-enol dehydrogenase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-2-butenoyl-CoA to 2-methyl-1 -but-2-enol e.g., 2-methyl-2-butenoyl- CoA reductase (Afunctional)
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-3-hydroxybutyryl-CoA to 2-methyl-3-hydroxybutanal e.g., 2-methyl-
  • 3- hydroxybutanal dehydrogenase 3- hydroxybutanal dehydrogenase
  • 2-methyl-1 ,3- butanediol dehydrogenase 2-methyl-1 ,3- butanediol dehydrogenase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methyl-3-hydroxybutyryl-CoA to 2-methyl-1 ,3-butanediol ⁇ e.g., 2-methyl-3- hydroxybutyryl-CoA reductase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methylbut-2-en-1-ol to isoprene ⁇ e.g., 2-methyl-1-but-2-enol dehydratase).
  • the one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of glucose to 2-methylacetoacetyl-CoA include:
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of fumarate to succinate ⁇ e.g., fumarate reductase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of succinate to succinyl-CoA e.g., succinyl-CoA synthase or succinyl-CoA transferase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of succinyl-CoA to (R)-ethylmalonyl-CoA ⁇ e.g., methylmalonyl-CoA mutase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of (R)-ethylmalonyl-CoA to (S)-ethylmalonyl-CoA ⁇ e.g., methylmalonyl-CoA epimerase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of (S)-ethylmalonyl-CoA to propanoyl-CoA ⁇ e.g., methylmalonyl-CoA decarboxylase); - one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of oxalacetate and acetyl-CoA to citrate ⁇ e.g., citrate synthase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of cis-aconitate to isocitrate ⁇ e.g., cis-aconitate hydratase
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of isocitrate to succinate and glyoxalate ⁇ e.g., isocitrate lyase;
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of glyoxalate and acetyl-CoA to malate ⁇ e.g., malate synthase);
  • polynucleotides coding for enzymes in a pathway that catalyze a conversion of propionyl-CoA and acetyl-CoA to 2-methylacetoacetyl-CoA ⁇ e.g., acetyl- CoA:propanoyl-CoA 2-C-acetyltransferase or 2-methylacetoacetyl-CoA thiolase).
  • Exemplary enzymes that convert a fermentable carbon source such as glucose to 2-methylacetoacetyl-CoA including, enzyme substrates, and enzyme reaction products associated with the conversions are presented in Table 2 below.
  • the enzyme reference identifier listed in Table 2 correlates with the enzyme numbering used in Figure 2, which schematically represents the enzymatic conversion of a fermentable carbon source such as glucose to 2-methylacetoacetyl-CoA.
  • 2-methylacetoacetyl-CoA may be further converted to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2- en-1 -ol using any combination of those enzymes provided in Table 1 above including, all of those enzymes as provided in Table 1 above.
  • the microorganism may be an archea, bacteria, or eukaryote.
  • the bacteria is a Propionibacterium, Propionispira, Clostridium, Bacillus, Escherichia, Burkholderia, Ralstonia, Pelobacter, or Lactobacillus including, for example, Pelobacter propionicus, Clostridium propionicum, Escherichia coli, Clostridium acetobutylicum, Lactobacillus, Propionibacterium acidipropionici or Propionibacterium freudenreichii.
  • the eukaryote is a yeast, filamentous fungi, protozoa, or algae.
  • the yeast is Saccharomyces cerevisiae or Pichia pastoris.
  • the microorganism is additionally modified to comprise one or more tolerance mechanisms including, for example, tolerance to a produced biofuel, and/or organic solvents.
  • a microorganism modified to comprise such a tolerance mechanism may provide a means to increase titers of fermentations and/or may control contamination in an industrial scale process.
  • the disclosure contemplates the modification ⁇ e.g., engineering) of one or more of the enzymes provided herein.
  • modification may be performed to redesign the substrate specificity of the enzyme and/or to modify ⁇ e.g., reduce) its activity against others substrates in order to increase its selectivity for a given substrate.
  • one or more enzymes as provided herein may be engineered to alter ⁇ e.g., enhance including, for example, increase its catalytic activity or its substrate specificity) one or more of its properties.
  • sequence alignment and comparative modeling of proteins may be used to alter one or more of the enzymes disclosed herein.
  • Homology modeling or comparative modeling refers to building an atomic-resolution model of the desired protein from its primary amino acid sequence and an experimental three- dimensional structure of a similar protein. This model may allow for the enzyme substrate binding site to be defined, and the identification of specific amino acid positions that may be replaced to other natural amino acid in order to redesign its substrate specificity.
  • variants or modified sequences having substantial identity or homology with the polynucleotides encoding enzymes as disclosed herein may be utilized in the practice of the disclosure. Such sequences can be referred to as variants or modified sequences. That is, a polynucleotide sequence may be modified yet still retain the ability to encode a polypeptide exhibiting the desired activity. Such variants or modified sequences are thus equivalents in the sense that they retain their intended function. Generally, the variant or modified sequence may comprise at least about 40%-60%, preferably about 60%-80%, more preferably about 80%-90%, and even more preferably about 90%-95% or 99% sequence identity with the native sequence.
  • a microorganism may be modified to express including, for example, overexpress, one or more enzymes as provided herein.
  • the microorganism may be modified by genetic engineering techniques (i.e., recombinant technology), classical microbiological techniques, or a combination of such techniques and can also include naturally occurring genetic variants to produce a genetically modified microorganism. Some of such techniques are generally disclosed, for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press.
  • a genetically modified microorganism may include a microorganism in which a polynucleotide has been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), in such a manner that such modifications provide the desired effect of expression (e.g., over-expression) of one or more enzymes as provided herein within the microorganism.
  • Genetic modifications which result in an increase in gene expression or function can be referred to as amplification, overproduction, overexpression, activation, enhancement, addition, or up-regulation of a gene.
  • Addition of cloned genes to increase gene expression can include maintaining the cloned gene(s) on replicating plasmids or integrating the cloned gene(s) into the genome of the production organism. Furthermore, increasing the expression of desired cloned genes can include operatively linking the cloned gene(s) to native or heterologous transcriptional control elements. [0078] Where desired, the expression of one or more of the enzymes provided herein are under the control of a regulatory sequence that controls directly or indirectly the expression of the enzyme in a time-dependent fashion during a fermentation reaction.
  • the disclosure contemplates the modification (e.g., engineering) of one or more of the enzymes provided herein.
  • modification may be performed to redesign the substrate specificity of the enzyme and/or to modify (e.g., reduce) its activity against others substrates in order to increase its selectivity for a given substrate.
  • one or more enzymes as provided herein may be engineered to alter (e.g., enhance including, for example, increase its catalytic activity or its substrate specificity) one or more of its properties.
  • Additional exemplary methods for mutagenesis of a polynucleotide include Heteroduplex Recombination (Volkov et al., Nucleic Acids Res. 27:e18 (1999); and Volkov et al., Methods Enzymol. 328:456-463 (2000)); Random Chimeragenesis on Transient Templates (RACHITT) (Coco et al., Nat. Biotechnol. 19:354-359 (2001 )); Recombined Extension on Truncated templates (RETT) (Lee et al., J. Molec.
  • a microorganism is transformed or transfected with a genetic vehicle such as, an expression vector comprising an exogenous polynucleotide sequence coding for the enzymes provided herein.
  • Polynucleotide constructs prepared for introduction into a prokaryotic or eukaryotic host may typically, but not always, comprise a replication system (i.e. vector) recognized by the host, including the intended polynucleotide fragment encoding the desired polypeptide, and may preferably, but not necessarily, also include transcription and translational initiation regulatory sequences operably linked to the polypeptide-encoding segment.
  • a replication system i.e. vector
  • Expression systems may include, for example, an origin of replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information sites, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional terminator sequences, mRNA stabilizing sequences, nucleotide sequences homologous to host chromosomal DNA, and/or a multiple cloning site.
  • Signal peptides may also be included where appropriate, preferably from secreted polypeptides of the same or related species, which allow the protein to cross and/or lodge in cell membranes or be secreted from the cell.
  • the vectors can be constructed using standard methods (see, e.g., Sambrook et al., Molecular Biology: A Laboratory Manual, Cold Spring Harbor, N.Y. 1989; and Ausubel, et al., Current Protocols in Molecular Biology, Greene Publishing, Co. N.Y, 1995).
  • the manipulation of polynucleotides of the present disclosure including polynucleotides coding for one or more of the enzymes disclosed herein is typically carried out in recombinant vectors.
  • Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial chromosomes, episomal vectors and gene expression vectors, which can all be employed.
  • a vector of use according to the disclosure may be selected to accommodate a protein coding sequence of a desired size.
  • a suitable host cell is transformed with the vector after in vitro cloning manipulations.
  • Host cells may be prokaryotic, such as any of a number of bacterial strains, or may be eukaryotic, such as yeast or other fungal cells, insect or amphibian cells, or mammalian cells including, for example, rodent, simian or human cells.
  • Each vector contains various functional components, which generally include a cloning site, an origin of replication and at least one selectable marker gene.
  • given vector is an expression vector, it additionally possesses one or more of the following: enhancer element, promoter, transcription termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a polypeptide repertoire member according to the disclosure.
  • Vectors may contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
  • the sequence may be one that enables the vector to replicate independently of the host chromosomal DNA and may include origins of replication or autonomously replicating sequences.
  • origins of replication or autonomously replicating sequences are well known for a variety of bacteria, yeast and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria
  • the 2 micron plasmid origin is suitable for yeast
  • various viral origins e.g. SV 40, adenovirus
  • the origin of replication is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
  • a cloning or expression vector may contain a selection gene also referred to as a selectable marker. This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium.
  • Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate, hygromycin, thiostrepton, apramycin or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
  • the replication of vectors may be performed in E. coli ⁇ e.g., strain TB1 or TG1 , DH5a, DH103, JM1 10).
  • An E. coli-selectable marker for example, the ⁇ -lactamase gene that confers resistance to the antibiotic ampicillin, may be of use.
  • These selectable markers can be obtained from E. coli plasmids, such as pBR322 or a pUC plasmid such as pUC18 or pUC19, or pUC1 19.
  • Expression vectors may contain a promoter that is recognized by the host organism.
  • the promoter may be operably linked to a coding sequence of interest. Such a promoter may be inducible or constitutive.
  • Polynucleotides are operably linked when the polynucleotides are in a relationship permitting them to function in their intended manner.
  • Viral promoters obtained from the genomes of viruses include promoters from polyoma virus, fowlpox virus, adenovirus (e.g., Adenovirus 2 or 5), herpes simplex virus (thymidine kinase promoter), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus (e.g., MoMLV, or RSV LTR), Hepatitis-B virus, Myeloproliferative sarcoma virus promoter (MPSV), VISNA, and Simian Virus 40 (SV40).
  • Heterologous mammalian promoters include, e.g., the actin promoter, immunoglobulin promoter, heat-shock protein promoters.
  • the early and late promoters of the SV40 virus are conveniently obtained as a restriction fragment that also contains the SV40 viral origin of replication (see, e.g., Fiers et al., Nature, 273:1 13 (1978); Mulligan and Berg, Science, 209:1422-1427 (1980); and Pavlakis et al., Proc. Natl. Acad. Sci. USA, 78:7398-7402 (1981 )).
  • the immediate early promoter of the human cytomegalovirus (CMV) is conveniently obtained as a Hind III E restriction fragment (see, e.g., Greenaway et al., Gene, 18:355-360 (1982)).
  • a broad host range promoter such as the SV40 early promoter or the Rous sarcoma virus LTR, is suitable for use in the present expression vectors.
  • a strong promoter may be employed to provide for high level transcription and expression of the desired product.
  • the eukaryotic promoters that have been identified as strong promoters for high-level expression are the SV40 early promoter, adenovirus major late promoter, mouse metallothionein-l promoter, Rous sarcoma virus long terminal repeat, and human cytomegalovirus immediate early promoter (CMV or CMV IE).
  • the promoter is a SV40 or a CMV early promoter.
  • the promoters employed may be constitutive or regulatable, e.g., inducible.
  • Exemplary inducible promoters include jun, fos and metallothionein and heat shock promoters.
  • One or both promoters of the transcription units can be an inducible promoter.
  • the GFP is expressed from a constitutive promoter while an inducible promoter drives transcription of the gene coding for one or more enzymes as disclosed herein and/or the amplifiable selectable marker.
  • the transcriptional regulatory region in higher eukaryotes may comprise an enhancer sequence.
  • enhancer sequences from mammalian genes are known e.g., from globin, elastase, albumin, ofetoprotein and insulin genes.
  • a suitable enhancer is an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the enhancer of the cytomegalovirus immediate early promoter (Boshart et al.
  • the enhancer sequences may be introduced into the vector at a position 5' or 3' to the gene of interest, but is preferably located at a site 5' to the promoter.
  • Yeast and mammalian expression vectors may contain prokaryotic sequences that facilitate the propagation of the vector in bacteria. Therefore, the vector may have other components such as an origin of replication (e.g., a nucleic acid sequence that enables the vector to replicate in one or more selected host cells), antibiotic resistance genes for selection in bacteria, and/or an amber stop codon which can permit translation to read through the codon. Additional eukaryotic selectable gene(s) may be incorporated.
  • the origin of replication is one that enables the vector to replicate independently of the host chromosomal DNA, and includes origins of replication or autonomously replicating sequences. Such sequences are well known, e.g., the ColE1 origin of replication in bacteria.
  • viral origins e.g., SV40, polyoma, adenovirus, VSV or BPV
  • SV40 polyoma, adenovirus, VSV or BPV
  • a eukaryotic replicon is not needed for expression in mammalian cells unless extrachromosomal (episomal) replication is intended (e.g., the SV40 origin may typically be used only because it contains the early promoter).
  • the constructs may be designed with at least one cloning site for insertion of any gene coding for any enzyme disclosed herein.
  • the cloning site may be a multiple cloning site, e.g., containing multiple restriction sites.
  • the plasmids may be propagated in bacterial host cells to prepare DNA stocks for subcloning steps or for introduction into eukaryotic host cells. Transfection of eukaryotic host cells can be any performed by any method well known in the art.
  • Transfection methods include lipofection, electroporation, calcium phosphate co-precipitation, rubidium chloride or polycation mediated transfection, protoplast fusion and microinjection.
  • the transfection is a stable transfection.
  • the transfection method that provides optimal transfection frequency and expression of the construct in the particular host cell line and type, is favored. Suitable methods can be determined by routine procedures.
  • the constructs are integrated so as to be stably maintained within the host chromosome.
  • Vectors may be introduced to selected host cells by any of a number of suitable methods known to those skilled in the art.
  • vector constructs may be introduced to appropriate cells by any of a number of transformation methods for plasmid vectors.
  • standard calcium-chloride-mediated bacterial transformation is still commonly used to introduce naked DNA to bacteria (see, e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), but electroporation and conjugation may also be used (see, e.g., Ausubel et al., 1988, Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, N.Y.).
  • yeast or other fungal cells For the introduction of vector constructs to yeast or other fungal cells, chemical transformation methods may be used ⁇ e.g., Rose et al., 1990, Methods in Yeast Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Transformed cells may be isolated on selective media appropriate to the selectable marker used. Alternatively, or in addition, plates or filters lifted from plates may be scanned for GFP fluorescence to identify transformed clones.
  • Plasmid vectors may be introduced by any of a number of transfection methods, including, for example, lipid-mediated transfection ("lipofection"), DEAE-dextran-mediated transfection, electroporation or calcium phosphate precipitation (see, e.g., Ausubel et al., 1988, Current Protocols in Molecular Biology, John Wiley & Sons, Inc., NY, N.Y.).
  • Lipofection reagents and methods suitable for transient transfection of a wide variety of transformed and non-transformed or primary cells are widely available, making lipofection an attractive method of introducing constructs to eukaryotic, and particularly mammalian cells in culture.
  • LipofectAMINETM Life Technologies
  • LipoTaxiTM LipoTaxiTM kits
  • Other companies offering reagents and methods for lipofection include Bio-Rad Laboratories, CLONTECH, Glen Research, InVitrogen, JBL Scientific, MBI Fermentas, PanVera, Promega, Quantum Biotechnologies, Sigma-Aldrich, and Wako Chemicals USA.
  • the host cell may be capable of expressing the construct encoding the desired protein, processing the protein and transporting a secreted protein to the cell surface for secretion. Processing includes co- and post-translational modification such as leader peptide cleavage, GPI attachment, glycosylation, ubiquitination, and disulfide bond formation.
  • Immortalized host cell cultures amenable to transfection and in vitro cell culture and of the kind typically employed in genetic engineering are preferred. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS- 7, ATCC CRL 1651 ); human embryonic kidney line (293 or 293 derivatives adapted for growth in suspension culture, Graham et al., J.
  • monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51 ); TRI cells (Mather et al., Annals N.Y. Acad. Sci., 383:44-68 (1982)); PEER human acute lymphoblastic cell line (Ravid et al.
  • MRC 5 cells MRC 5 cells; FS4 cells; human hepatoma line (Hep G2), human HT1080 cells, KB cells, JW-2 cells, Detroit 6 cells, NIH-3T3 cells, hybridoma and myeloma cells.
  • Embryonic cells used for generating transgenic animals are also suitable (e.g., zygotes and embryonic stem cells).
  • Suitable host cells for cloning or expressing polynucleotides (e.g., DNA) in vectors may include, for example, prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes for this purpose include eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B.
  • subtilis and B. licheniformis e.g., B. licheniformis 41 P disclosed in DD 266,710 published Apr. 12, 1989
  • Pseudomonas such as P. aeruginosa
  • Streptomyces One preferred E. coli cloning host is E. coli 294 (ATCC 31 ,446), although other strains such as E. coli B, E. coli X1776 (ATCC 31 ,537), E. coli JM1 10 (ATCC 47,013) and E. coli W31 10 (ATCC 27,325) are suitable.
  • eukaryotic microbes such as filamentous fungi or yeast may be suitable cloning or expression hosts for vectors comprising polynucleotides coding for one or more enzymes.
  • Saccharomyces cerevisiae or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms.
  • a number of other genera, species, and strains are commonly available and useful herein, such as Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K. fragilis (ATCC 12,424), K. bulgaricus (ATCC 16,045), K.
  • wickeramii ATCC 24,178
  • K. waltii ATCC 56,500
  • K. drosophilarum ATCC 36,906
  • K. thermotolerans K. marxianus
  • yarrowia EP 402,226
  • Pichia pastors EP 183,070
  • Candida Trichoderma reesia
  • Neurospora crassa Neurospora crassa
  • Schwanniomyces such as Schwanniomyces occidentalis
  • filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium, and Aspergillus hosts such as A. nidulans and A. niger.
  • suitable host cells for expression may be derived from multicellular organisms.
  • invertebrate cells include plant and insect cells.
  • Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruitfly), and Bombyx mori (silk moth) have been identified.
  • a variety of viral strains for transfection are publicly available, e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used as the virus herein according to the present disclosure, particularly for transfection of Spodoptera frugiperda cells.
  • Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, tobacco, lemna, and other plant cells can also be utilized as host cells.
  • Examples of useful mammalian host cells are Chinese hamster ovary cells, including CHOK1 cells (ATCC CCL61 ), DXB-1 1 , DG-44, and Chinese hamster ovary cells/- DHFR (CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77: 4216 (1980)); monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651 ); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, (Graham et al., J. Gen Virol. 36: 59, 1977); baby hamster kidney cells (BHK, ATCC CCL 10); mouse Sertoli cells (TM4, Mather, (Biol.
  • monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51 ); TRI cells (Mather et al., Annals N.Y Acad. Sci.
  • Host cells are transformed or transfected with the above-described expression or cloning vectors for production of one or more enzymes as disclosed herein or with polynucleotides coding for one or more enzymes as disclosed herein and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • Host cells containing desired nucleic acid sequences coding for the disclosed enzymes may be cultured in a variety of media.
  • Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells.
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adeNOSine and thymidine), antibiotics (such as GENTAMYCINTM drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • any known polynucleotide e.g., gene
  • Such polynucleotides may be modified (e.g., genetically engineered) to modulate (e.g., increase or decrease) the substrate specificity of an encoded enzyme, or the polynucleotides may be modified to change the substrate specificity of the encoded enzyme (e.g., a polynucleotide that codes for an enzyme with specificity for a substrate may be modified such that the enzyme has specificity for an alternative substrate).
  • Preferred microorganisms may comprise polynucleotides coding for one or more of the enzymes as set forth in any one of Tables 1 - 2 and Figure 1 - 2.
  • Enzymes, and polynucleotides encoding same, for catalyzing the conversions in Tables 1-2 and Figures 1 -2 are categorized in Table 3-4, respectively, by Enzyme Commission (EC) number, function, and the step in Tables 1-2 and Figures 1-2 in which they catalyze a conversion.
  • EC Enzyme Commission
  • Isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en- 1 -ol may be produced by contacting any of the disclosed genetically modified microorganisms with a fermentable carbon source.
  • Such methods may preferably comprise contacting a fermentable carbon source with a microorganism comprising one or more polynucleotides coding for enzymes in a pathway that catalyze the conversion of the fermentable carbon source into any of the intermediates provided in either of Tables 1-2 or Figures 1-2 and one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion one or more of the intermediates provided in Figures 1-2 (Tables 1 - 2) into isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol in a fermentation media; and expressing the one or more polynucleotides coding for the enzymes in the pathway that catalyzes the conversion of the fermentable carbon source into one or more of the intermediates provided in Figures 1 -2 (Tables 1 -2) and one or more polynucleotides coding for enzymes in a pathway that cat
  • the conversion of the fermentable carbon source to isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3- butanediol, and/or 2-methylbut-2-en-1 -ol is ATP positive (e.g., generates a net of ATP per mol of butadiene produced; produces ATP as a byproduct) and when combined with a NADH consuming pathway it can provide an anaerobic process for isoprene, 2-methyl-1- butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol production.
  • Exemplary fermentable carbon sources may include, but are not limited to, sugarcane juice, sugarcane molasses, hydrolyzed starch, hydrolyzed lignocellulosic materials, glucose, sucrose, fructose, lactate, lactose, xylose, pyruvate, or glycerol in any form or mixture thereof.
  • the carbon source is a monosaccharide, oligosaccharide, or polysaccharide.
  • Metabolic pathways that lead to the production of industrially important compounds such as isoprene involve oxidation-reduction (redox) reactions.
  • redox oxidation-reduction
  • glucose is oxidized in a series of enzymatic reactions into smaller molecules with the concomitant release of energy.
  • the electrons released are transferred from one reaction to another through universal electron carriers, such Nicotinamide Adenine Dinucleotide (NAD) and Nicotinamide Adenine Dinucleotide Phosphate (NAD(P)), which act as cofactors for oxidoreductase enzymes.
  • NAD Nicotinamide Adenine Dinucleotide
  • NAD(P) Nicotinamide Adenine Dinucleotide Phosphate
  • glucose is oxidized by enzymes using the oxidized form of the cofactors (NAD(P)+ and/or NAD+) as cofactor thus generating reducing equivalents in the form of the reduced cofactor (NAD(P)H and NADH).
  • NAD(P)+ and/or NAD+ the cofactors
  • red ox-balanced metabolism is required, i.e., the cofactors must be regenerated by the reduction of microbial cell metabolic compounds.
  • the novel pathways disclosed herein are advantageous in that they provide for the conversion of a fermentable carbon source to isoprene through a pathway that redistributes the end products to achieve a redox balance.
  • Microorganism-catalyzed fermentation for the production of natural products is a widely known application of biocatalysis.
  • Industrial microorganisms can affect multistep conversions of renewable feedstocks to high value chemical products in a single reactor.
  • Products of microorganism-catalyzed fermentation processes range from chemicals such as ethanol, lactic acid, amino acids and vitamins, to high value small molecule pharmaceuticals, protein pharmaceuticals, and industrial enzymes.
  • the biocatalysts are whole-cell microorganisms, including microorganisms that have been genetically modified to express heterologous genes.
  • Some key parameters for efficient microorganism-catalyzed fermentation processes include the ability to grow microorganisms to a greater cell density, increased yield of desired products, increased amount of volumetric productivity, removal of unwanted co-metabolites, improved utilization of inexpensive carbon and nitrogen sources, adaptation to varying fermenter conditions, increased production of a primary metabolite, increased production of a secondary metabolite, increased tolerance to acidic conditions, increased tolerance to basic conditions, increased tolerance to organic solvents, increased tolerance to high salt conditions and increased tolerance to high or low temperatures. Inefficiencies in any of these parameters can result in high manufacturing costs, inability to capture or maintain market share, and/or failure to bring fermented end-products to market.
  • compositions of the present disclosure can be adapted to conventional fermentation bioreactors (e.g., batch, fed-batch, cell recycle, and continuous fermentation).
  • a microorganism e.g., a genetically modified microorganism as provided herein is cultivated in liquid fermentation media (i.e., a submerged culture) which leads to excretion of the fermented product(s) into the fermentation media.
  • the fermented end product(s) can be isolated from the fermentation media using any suitable method known in the art.
  • formation of the fermented product occurs during an initial, fast growth period of the microorganism. In one embodiment, formation of the fermented product occurs during a second period in which the culture is maintained in a slow-growing or quiescent state. In one embodiment, formation of the fermented product occurs during more than one growth period of the microorganism. In such embodiments, the amount of fermented product formed per unit of time is generally a function of the metabolic activity of the microorganism, the physiological culture conditions (e.g., pH, temperature, medium composition), and the amount of microorganisms present in the fermentation process.
  • the physiological culture conditions e.g., pH, temperature, medium composition
  • the fermentation product is recovered from the periplasm or culture medium as a secreted metabolite.
  • the fermentation product is extracted from the microorganism, for example when the microorganism lacks a secretory signal corresponding to the fermentation product.
  • the microorganisms are ruptured and the culture medium or lysate is centrifuged to remove particulate cell debris. The membrane and soluble protein fractions may then be separated if necessary.
  • the fermentation product of interest may then be purified from the remaining supernatant solution or suspension by, for example, distillation, fractionation, chromatography, precipitation, filtration, and the like.
  • the microorganism cells (or portions thereof) may be used as biocatalysts or for other functions in a subsequent process without substantial purification.
  • 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol are further converted to isoprene including, for example, polyisoprene or another isoprene- containing polymer by any method known in the art (see, Figure 3).
  • Isoprene produced via any of the disclosed processes or methods may be converted to polyisoprene, lattices of polyisoprene, Styrene-lsoprene-Styrene (SIS) Block Copolymer, and styrene/isoprene/ butadiene rubber (SI BR).
  • SIS Styrene-lsoprene-Styrene
  • SI BR styrene/isoprene/ butadiene rubber
  • Example 1 Modification of microorganism for production of isoprene, 2-methyl-1 - butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • a microorganism such as a bacterium is genetically modified to produce isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1-ol from a fermentable carbon source including, for example, glucose.
  • a microorganism may be genetically engineered by any methods known in the art to comprise: i.) one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of the fermentable carbon source to 2- methylacetoacetly-CoA and one or more polynucleotides coding for enzymes in a pathway that catalyze a conversion of 2-methylacetoacetly-CoA to isoprene, 2-methyl-1-butanol, 2- methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • a microorganism that lacks one or more enzymes ⁇ e.g., one or more functional enzymes that are catalytically active) for the conversion of a fermentable carbon source to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en- 1 -ol may be genetically modified to comprise one or more polynucleotides coding for enzymes ⁇ e.g., functional enzymes including, for example any enzyme disclosed herein) in a pathway that the microorganism lacks to catalyze a conversion of the fermentable carbon source to isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en- 1-ol.
  • Example 2 Fermentation of glucose by genetically modified microorganism to produce isoprene, 2-methyl-1 -butanol, 2-methyl-1 ,3-butanediol, and/or 2-methylbut-2-en-1 -ol.
  • a genetically modified microorganism, as produced in Example 1 above, may be used to ferment a carbon source producing isoprene, 2-methyl-1-butanol, 2-methyl-1 ,3- butanediol, and/or 2-methylbut-2-en-1 -ol..
  • anaerobic conditions are maintained by, for example, sparging nitrogen through the culture medium.
  • a suitable temperature for fermentation e.g., about 30 °C
  • a near physiological pH e.g., about 6.5
  • the bioreactor is agitated at, for example, about 50 rpm. Fermentation is allowed to run to completion.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne généralement des micro-organismes (par exemple, des micro-organismes non naturels) qui comprennent un ou plusieurs polynucléotides codant pour des enzymes dans une voie qui catalysent la conversion d'une source de carbone (par exemple, une source de carbone fermentescible) en isoprène, 2-méthyl-1-butanol, 2-méthyl-1,3-butanediol, et/ou 2-méthyl-but-2-én-1-ol et l'utilisation de ces micro-organismes pour la production d'isoprène, 2-méthyl-1-butanol, 2-méthyl-1,3-butanediol, et/ou 2-méthyl-but-2-én-1-ol.
PCT/US2013/075692 2012-12-17 2013-12-17 Micro-organismes modifiés et procédés d'utilisation de ceux-ci pour produire de l'isoprène, du 2-méthyl-1-butanol, du 2-méthyl-1,3-butanediol, et/ou du 2-méthyl-but-2-én-1-ol WO2014099927A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738217P 2012-12-17 2012-12-17
US61/738,217 2012-12-17

Publications (1)

Publication Number Publication Date
WO2014099927A1 true WO2014099927A1 (fr) 2014-06-26

Family

ID=50979107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/075692 WO2014099927A1 (fr) 2012-12-17 2013-12-17 Micro-organismes modifiés et procédés d'utilisation de ceux-ci pour produire de l'isoprène, du 2-méthyl-1-butanol, du 2-méthyl-1,3-butanediol, et/ou du 2-méthyl-but-2-én-1-ol

Country Status (1)

Country Link
WO (1) WO2014099927A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017001975A (ja) * 2015-06-08 2017-01-05 国立大学法人 千葉大学 不飽和アルコールの製造方法及び触媒

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009005A (en) * 1959-06-12 1961-11-14 Scient Desing Company Inc Chemical process
WO2008034648A1 (fr) * 2006-04-05 2008-03-27 Metanomics Gmbh Procédé de production d'un produit chimique fin
US20100048964A1 (en) * 2008-07-02 2010-02-25 Calabria Anthony R Compositions and methods for producing isoprene free of c5 hydrocarbons under decoupling conditions and/or safe operating ranges
US20100167370A1 (en) * 2008-09-15 2010-07-01 Chotani Gopal K Reduction of carbon dioxide emission during isoprene production by fermentation
US20100167371A1 (en) * 2008-09-15 2010-07-01 Chotani Gopal K Systems using cell culture for production of isoprene
US20100184173A1 (en) * 2008-11-14 2010-07-22 Genomatica, Inc. Microorganisms for the production of methyl ethyl ketone and 2-butanol
US20100196977A1 (en) * 2008-12-30 2010-08-05 Chotani Gopal K Methods of producing isoprene and a co-product
US20100209986A1 (en) * 2007-02-09 2010-08-19 The Regents Of The University Of California Biofuel production by recombinant microorganisms
US20100216958A1 (en) * 2009-02-24 2010-08-26 Peters Matthew W Methods of Preparing Renewable Butadiene and Renewable Isoprene
US20110040058A1 (en) * 2009-06-17 2011-02-17 Mcauliffe Joseph C Polymerization of isoprene from renewable resources
US20110201072A1 (en) * 2010-02-12 2011-08-18 Gevo, Inc. Modified alcohol dehydrogenases for the production of fuels and chemicals
US20130122563A1 (en) * 2011-09-16 2013-05-16 Mark J. Burk Microorganisms and methods for producing alkenes

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009005A (en) * 1959-06-12 1961-11-14 Scient Desing Company Inc Chemical process
WO2008034648A1 (fr) * 2006-04-05 2008-03-27 Metanomics Gmbh Procédé de production d'un produit chimique fin
US20100209986A1 (en) * 2007-02-09 2010-08-19 The Regents Of The University Of California Biofuel production by recombinant microorganisms
US20100048964A1 (en) * 2008-07-02 2010-02-25 Calabria Anthony R Compositions and methods for producing isoprene free of c5 hydrocarbons under decoupling conditions and/or safe operating ranges
US20100167370A1 (en) * 2008-09-15 2010-07-01 Chotani Gopal K Reduction of carbon dioxide emission during isoprene production by fermentation
US20100167371A1 (en) * 2008-09-15 2010-07-01 Chotani Gopal K Systems using cell culture for production of isoprene
US20100184173A1 (en) * 2008-11-14 2010-07-22 Genomatica, Inc. Microorganisms for the production of methyl ethyl ketone and 2-butanol
US20100196977A1 (en) * 2008-12-30 2010-08-05 Chotani Gopal K Methods of producing isoprene and a co-product
US20100216958A1 (en) * 2009-02-24 2010-08-26 Peters Matthew W Methods of Preparing Renewable Butadiene and Renewable Isoprene
US20110040058A1 (en) * 2009-06-17 2011-02-17 Mcauliffe Joseph C Polymerization of isoprene from renewable resources
US20110201072A1 (en) * 2010-02-12 2011-08-18 Gevo, Inc. Modified alcohol dehydrogenases for the production of fuels and chemicals
US20130122563A1 (en) * 2011-09-16 2013-05-16 Mark J. Burk Microorganisms and methods for producing alkenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017001975A (ja) * 2015-06-08 2017-01-05 国立大学法人 千葉大学 不飽和アルコールの製造方法及び触媒

Similar Documents

Publication Publication Date Title
US10273505B2 (en) Modified microorganisms and methods of making butadiene using same
WO2013192183A1 (fr) Microorganismes modifiés et procédés de coproduction de butadiène avec du 1-propanol et/ou du 1,2-propanediol
US20140134687A1 (en) Modified microorganisms and methods of using same for producing butadiene and succinate
US20150064760A1 (en) Modified microorganism and methods of using same for producing butadiene and 1-propanol and/or 1,2-propanediol
EP3149187B1 (fr) Micro-organismes modifiés comprenant un système optimisé pour l'utilisation d'oligosaccharides et procédés pour les utiliser
US10774317B2 (en) Engineered enzyme having acetoacetyl-CoA hydrolase activity, microorganisms comprising same, and methods of using same
WO2012109534A2 (fr) Cellules et procédés de production d'acide isobutyrique
US20150211024A1 (en) Methods for production of a terpene and a co-product
WO2015002977A1 (fr) Microorganismes modifiés et procédés d'utilisation de ces derniers pour la coproduction anaérobie d'isoprène et d'acide acétique
WO2014063156A2 (fr) Micro-organismes modifiés et leurs procédés d'utilisation pour produire du butadiène et un ou plusieurs parmi le 1,3-butanediol, le 1,4-butanediol et/ou le 1,3-propanediol
WO2014099927A1 (fr) Micro-organismes modifiés et procédés d'utilisation de ceux-ci pour produire de l'isoprène, du 2-méthyl-1-butanol, du 2-méthyl-1,3-butanediol, et/ou du 2-méthyl-but-2-én-1-ol
WO2015141705A1 (fr) Procédé permettant de conférer la résistance aux acides et la résistance au sel, et procédé de production de substances utiles faisant appel à une levure résistant aux acides, résistant au sel
US20150240264A1 (en) Methods for co-production of a terpene, succinate and hydrogen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13865356

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13865356

Country of ref document: EP

Kind code of ref document: A1